Literature DB >> 26024284

Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies.

Özgür Kara1, Pinar Zarakolu, Sibel Aşçioğlu, Sezgin Etgül, Burak Uz, Yahya Büyükaşik, Murat Akova.   

Abstract

BACKGROUND: The objective of this study was determine the frequency of bloodstream infections (BSIs) and the causative bacteria and their resistance patterns in patients with hematological malignancies (HMs) in a large tertiary care university hospital in Turkey over a 5-year period.
METHODS: A total of 2098 patients with HMs with 3703 neutropenic episodes were included. Patients were classified as high-risk (n = 843) and low-risk (n = 1255) groups and evaluated for frequency of BSIs, causative bacteria, and their resistance patterns.
RESULTS: The frequency of BSIs was 14.5%. The frequency of gram-negative BSIs in high-risk and low-risk groups was 10.7% and 5.4% (p < 0.001), respectively. The frequency of gram-positive BSIs in high-risk and low-risk groups was 7.0% and 3.9% (p < 0.001), respectively. Gram-negative bacteria predominated (52.6%), with Escherichia coli (17.3%) and Klebsiella spp. (11.0%) as the most frequent organisms. Coagulase-negative staphylococci (10.4%) and Corynebacterium spp. (6.3%) were the most common gram-positive bacteria (35.8%). The rate of extended-spectrum beta-lactamase (ESBL) production was 45% for E. coli and 58% for Klebsiella spp. Quinolone resistance was 58% for E. coli and 11% for Klebsiella spp.. The overall frequency of ceftazidime resistance in Pseudomonas aeruginosa was 28%, and 87% of Acinetobacter spp. were multidrug-resistant. Of Staphylococcus aureus isolates, 24.8% were resistant to methicillin.
CONCLUSION: The dominating causes of BSIs in patients with HMs in our hospital are resistant gram-negative bacteria, which has made empirical antimicrobial choice a highly challenging issue in this patient population.

Entities:  

Keywords:  Bloodstream infection; antimicrobial resistance; bacteremia; hematologic malignancy; neutropenia

Mesh:

Substances:

Year:  2015        PMID: 26024284     DOI: 10.3109/23744235.2015.1051105

Source DB:  PubMed          Journal:  Infect Dis (Lond)        ISSN: 2374-4243


  17 in total

Review 1.  Epidemiology of antimicrobial resistance in bloodstream infections.

Authors:  Murat Akova
Journal:  Virulence       Date:  2016-04-02       Impact factor: 5.882

2.  Prognostic factors and scoring model of hematological malignancies patients with bloodstream infections.

Authors:  Yishu Tang; Qian Cheng; Qing Yang; Jing Liu; Di Zhang; Wei Cao; Qingxia Liu; Tianyi Zhou; Huiqi Zeng; Li Zhou; QinJin Wang; Huan Wei; Xin Li
Journal:  Infection       Date:  2018-05-16       Impact factor: 3.553

Review 3.  The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies.

Authors:  Thomas M Baker; Michael J Satlin
Journal:  Leuk Lymphoma       Date:  2016-06-24

Review 4.  Antibacterial Resistance in Patients with Hematopoietic Stem Cell Transplantation.

Authors:  Sehnaz Alp; Murat Akova
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-01-01       Impact factor: 2.576

5.  Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance.

Authors:  Carolina Garcia-Vidal; Celia Cardozo-Espinola; Pedro Puerta-Alcalde; Francesc Marco; Adrian Tellez; Daiana Agüero; Francisco Romero-Santana; Marina Díaz-Beyá; Eva Giné; Laura Morata; Olga Rodríguez-Núñez; Jose Antonio Martinez; Josep Mensa; Jordi Esteve; Alex Soriano
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

6.  [Distribution and drug resistance of pathogens of blood stream infection in patients with hematological malignancies after chemotherapy].

Authors:  S Z Chen; K N Lin; M Xiao; X F Luo; Q Li; J H Ren; R Y Huang; M M Chen; Z Z Ally; T Chen; J D Yang; Jianda Hu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-11-14

7.  [Clinical and bacteriological analysis of lymphoid tissue neoplasms patients with bacteria bloodstream infections].

Authors:  T Y Wang; Z J Li; Q S Lin; D Su; R Lyu; S H Deng; W W Sui; M W Fu; W Y Huang; W Liu; H Liu; L G Qiu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-12-14

8.  Impact of antibiotic resistance on outcomes of neutropenic cancer patients with Pseudomonas aeruginosa bacteraemia (IRONIC study): study protocol of a retrospective multicentre international study.

Authors:  Adaia Albasanz-Puig; Carlota Gudiol; Rocío Parody; Cristian Tebe; Murat Akova; Rafael Araos; Anna Bote; Anne-Sophie Brunel; Sebnem Calik; Lubos Drgona; Estefanía García; Philipp Hemmati; Fabián Herrera; Karim Yaqub Ibrahim; Burcu Isler; Souha Kanj; Winfried Kern; Guillermo Maestro de la Calle; Adriana Manzur; Jorge Iván Marin; Ignacio Márquez-Gómez; Pilar Martín-Dávila; Malgorzata Mikulska; José Miguel Montejo; Milagros Montero; Hugo Manuel Paz Morales; Isabel Morales; Andrés Novo; Chiara Oltolini; Maddalena Peghin; Jose Luis Del Pozo; Pedro Puerta-Alcalde; Isabel Ruiz-Camps; Oguz Resat Sipahi; Robert Tilley; Lucrecia Yáñez; Marisa Zenaide Ribeiro Gomes; Jordi Carratalà
Journal:  BMJ Open       Date:  2019-05-24       Impact factor: 2.692

9.  Prospective Evaluation of Infection Episodes in Cancer Patients in a Tertiary Care Academic Center: Microbiological Features and Risk Factors for Mortality.

Authors:  Nursel Çalık Başaran; Ergun Karaağaoğlu; Gülşen Hasçelik; Mine Durusu Tanrıöver; Murat Akova
Journal:  Turk J Haematol       Date:  2016-04-18       Impact factor: 1.831

10.  Antimicrobial utilization and antimicrobial resistance in patients with haematological malignancies in Japan: a multi-centre cross-sectional study.

Authors:  Wataru Mimura; Haruhisa Fukuda; Manabu Akazawa
Journal:  Ann Clin Microbiol Antimicrob       Date:  2020-02-17       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.